Growth Factor Signaling in 4R-Tauopathies

Growth Factor Signaling in 4R-Tauopathies

<div class="infobox infobox-mechanism">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">Growth Factor Signaling in 4R-Tauopathies</th></tr>
<tr><td><b>Diseases Covered</b></td><td>PSP, CBD, AGD, GGT, FTDP-17</td></tr>
<tr><td><b>Growth Factors</b></td><td>IGF1, BDNF, NGF, FGF, GDNF, NT-3, NT-4</td></tr>
<tr><td><b>Key Pathways</b></td><td>PI3K/Akt, MAPK/ERK, mTOR, PLCγ</td></tr>
<tr><td><b>Receptors</b></td><td>TrkA, TrkB, TrkC, FGFR, IGF-1R, RET</td></tr>
</table>
</div>

Overview

Growth factor signaling is a critical pathway network that regulates neuronal survival, synaptic plasticity, and trophic support in the central nervous system. In 4R-tauopathies—including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17)—dysregulation of growth factor signaling contributes to disease pathogenesis through multiple mechanisms[@pspngf][@cbsgdnf].

The 4R-tauopathies share common features including:

• Aggregation of 4-repeat (4R) tau isoforms
• Neuronal and glial tau pathology
• Progressive motor and cognitive decline
• Variable involvement of subcortical structures

Growth factor signaling provides essential neurotrophic support to neurons affected in these disorders. Understanding the shared and disease-specific alterations in this signaling network offers therapeutic opportunities.

Growth Factor Families

Neurotrophins

...

Growth Factor Signaling in 4R-Tauopathies

<div class="infobox infobox-mechanism">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">Growth Factor Signaling in 4R-Tauopathies</th></tr>
<tr><td><b>Diseases Covered</b></td><td>PSP, CBD, AGD, GGT, FTDP-17</td></tr>
<tr><td><b>Growth Factors</b></td><td>IGF1, BDNF, NGF, FGF, GDNF, NT-3, NT-4</td></tr>
<tr><td><b>Key Pathways</b></td><td>PI3K/Akt, MAPK/ERK, mTOR, PLCγ</td></tr>
<tr><td><b>Receptors</b></td><td>TrkA, TrkB, TrkC, FGFR, IGF-1R, RET</td></tr>
</table>
</div>

Overview

Growth factor signaling is a critical pathway network that regulates neuronal survival, synaptic plasticity, and trophic support in the central nervous system. In 4R-tauopathies—including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17)—dysregulation of growth factor signaling contributes to disease pathogenesis through multiple mechanisms[@pspngf][@cbsgdnf].

The 4R-tauopathies share common features including:

• Aggregation of 4-repeat (4R) tau isoforms
• Neuronal and glial tau pathology
• Progressive motor and cognitive decline
• Variable involvement of subcortical structures

Growth factor signaling provides essential neurotrophic support to neurons affected in these disorders. Understanding the shared and disease-specific alterations in this signaling network offers therapeutic opportunities.

Growth Factor Families

Neurotrophins

The neurotrophin family includes Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), and Neurotrophin-4 (NT-4). These proteins signal through Trk (tropomyosin receptor kinase) receptors and p75^NTR[@nrtau]:

| Neurotrophin | Primary Receptor | Key Functions |
|------------|-----------------|--------------|
| NGF | TrkA | Cholinergic neuron survival, memory |
| BDNF | TrkB | Synaptic plasticity, cognition |
| NT-3 | TrkC | Motor neuron support |
| NT-4 | TrkB | Synaptic maintenance |

NGF supports basal forebrain cholinergic neurons that degenerate in PSP and CBD. BDNF through TrkB signaling is critical for synaptic function and is impaired in several 4R-tauopathies[@bdntau][@trkb].

Insulin-Like Growth Factors

IGF1 (Insulin-like Growth Factor 1) signals through IGF-1R and activates PI3K/Akt and MAPK pathways. IGF1 has neuroprotective properties and modifies tau pathology[@igf1tau][@pi3katau]:

• PI3K/Akt pathway: Promotes neuronal survival through Akt phosphorylation
• mTOR signaling: Regulated by IGF1, coordinates protein synthesis and autophagy
• Tau phosphorylation: IGF1 signaling intersects with GSK-3β and CDK5

IGF1 is particularly relevant in GGT where oligodendroglial pathology may affect IGF signaling[@ggfigf1].

Fibroblast Growth Factors

The FGF family includes multiple members with neurotrophic properties:

• FGF2 (bFGF): Supports neurogenesis and neuronal survival[@fgf2neuro]
• FGF20: Selective dopaminergic neurotrophic factor[@fgf20]
• FGF18: Involved in neuroprotection

FGF signaling through FGFR (Fibroblast Growth Factor Receptor) activates both MAPK/ERK and PI3K/Akt pathways[@mapktau].

GDNF Family

GDNF (Glial Cell Line-Derived Neurotrophic Factor) and related proteins signal through RET receptor complex:

• GDNF: Potent dopaminergic neuron survival factor
• Neurturin (NRTN): GDNF family member
• ARTN (Artemin): GDNF family member
• CDNF: Cerebral dopamine neurotrophic factor

GDNF family signaling is important for dopaminergic neurons affected in PSP[@gdneuro].

Signaling Pathways

PI3K/Akt Pathway

The PI3K/Akt pathway is a central mediator of growth factor signaling:

PI3K/Akt dysregulation contributes to tau hyperphosphorylation and synaptic dysfunction in 4R-tauopathies["@pi3katau"].

MAPK/ERK Pathway

The MAPK/ERK pathway mediates growth factor effects on neuronal plasticity:

• Growth factor binding → Ras activation → Raf → MEK → ERK
• ERK enters nucleus → Transcription factor activation
• Cytoplasmic ERK → Synaptic plasticity modulation
• ERK activity is altered in tauopathies

mTOR Pathway

The mTOR pathway integrates growth factor and nutrient signals:

• mTORC1: Protein synthesis, autophagy regulation
• mTORC2: Cell survival, cytoskeletal regulation
• IGF1 → Akt → mTOR: Key signaling axis
• mTOR regulates BDNF expression and signaling[@mtorbdnf]

Dysregulated mTOR signaling contributes to impaired autophagy in 4R-tauopathies.

Disease-Specific Mechanisms

Progressive Supranuclear Palsy

In PSP, growth factor alterations include:

NGF and cholinergic signaling:

• NGF supports basal forebrain cholinergic neurons
• PSP shows cholinergic deficits in midbrain structures
• Cholinergic dysfunction contributes to oculomotor deficits

BDNF signaling:

• BDNF/TrkB signaling is impaired
• Contributes to cortical and subcortical dysfunction
• Synaptic plasticity deficits

IGF1:

• IGF1 signaling altered in PSP brain
• Modulates tau pathology in PSP models
• Potential therapeutic target

Corticobasal Degeneration

CBD involves multiple growth factor systems:

GDNF signaling:

• GDNF supports corticostriatal neurons
• RET receptor expression altered in CBD
• Therapeutic potential for corticobasal circuits[@cbsgdnf]

FGF signaling:

• FGF2 supports cortical neuron survival
• Altered in cortical degeneration
• Astrocyte involvement

BDNF:

• TrkB signaling crucial for cortical plasticity
• Impaired in CBD motor cortex
• Contributes to apraxia

Argyrophilic Grain Disease

AGD shows growth factor changes:

FGF expression:

• FGF alterations in affected brain regions
• Astrocytic involvement
• Related to grain formation[@agdfgf]

Neurotrophin signaling:

• Age-related decline in neurotrophins
• Contributes to neuronal vulnerability
• Relationship to argyrophilic grains

Globular Glial Tauopathy

GGT shows unique growth factor profiles:

IGF1 signaling:

• IGF1 in oligodendrocytes
• Altered in globular glial pathology[@ggfigf1]
• White matter involvement

FGF signaling:

• Astrocytic FGF expression
• Oligodendroglial support
• Related to globular inclusions

FTDP-17

FTDP-17 with MAPT mutations shows:

BDNF dysfunction:

• BDNF signaling altered by tau mutations[@ftdpbdnf]
• Synaptic deficits
• Cognitive decline

Neurotrophin signaling:

• tau interacts with Trk signaling
• Altered neuronal survival signaling
• Age-related exacerbation

Cross-Disease Comparison

| Growth Factor | PSP | CBD | AGD | GGT | FTDP-17 |
|--------------|-----|-----|-----|-----|--------|
| NGF/Choline | ↓↓ | ↓↓ | ↓ | ↓ | ↓ |
| BDNF/TrkB | ↓↓ | ↓↓ | ↓ | ↓↓ | ↓↓ |
| IGF1 | ↓ | ↓ | ↓ | ↓↓ | ↓ |
| FGF2 | ↓ | ↓ | ↓↓ | ↓ | ↓ |
| GDNF | ↓ | ↓↓ | ↓ | ↓ | ↓ |

↑ = Increased, ↓ = Decreased, ↓↓ = Severely decreased

Shared Mechanisms

All 4R-tauopathies show:

Age-related neurotrophin decline: Natural age-related decreases

Impaired PI3K/Akt signaling: Central to all

Synaptic plasticity deficits: Via BDNF/TrkB

mTOR dysregulation: Common pathway

Autophagy impairment: Related to growth factor signaling

Unique Features

• PSP: NGF/cholinergic emphasis, brainstem
• CBD: GDNF/RET, cortical-striatal
• AGD: FGF/astrocytic, limbic
• GGT: IGF1/oligodendroglial, white matter
• FTDP-17: BDNF/TrkB, synaptic

Therapeutic Implications

Neurotrophin-Based Therapies

BDNF delivery:

• AAV-BDNF gene therapy
• Small molecule TrkB agonists
• Novel delivery methods

NGF therapy:

• NGF infusion (historical)
• AAV-NGF delivery
• Small molecule agonists

Growth Factor Mimetics

Small molecule approaches:

• Selaginella polyphenols: Enhance neurotrophin expression[@seltin]
• Rosiglitazone: PPARγ agonist with neurotrophic effects[@rosiglitneuro]

Receptor agonists:

• TrkB agonist compounds
• IGF-1R modulators
• FGFR agonists

Targeting Common Pathways

mTOR modulation:

• Rapamycin: mTOR inhibitor
• Everolimus derivative
• Autophagy induction[@ampad]

PI3K/Akt modulation:

• Akt activators
• PI3K modulators
• Downstream effectors

Biomarker Applications

Peripheral Biomarkers

Growth factor levels in blood:

• BDNF serum: Correlates with disease progression
• IGF-1: Peripheral biomarker candidate
• FGF: Disease-specific patterns

CSF Biomarkers

Cerebrospinal fluid measurements:

• NGF: Changed in PSP
• BDNF: Disease monitoring
• IGF-1: Therapeutic response

Research Directions

Novel Delivery Methods

• Intranasal delivery: Bypasses BBB
• Exosome delivery: Native tropism
• Focused ultrasound: Enhanced delivery

Combination Approaches

• Multiple growth factors
• Gene therapy with small molecules
• Cell therapy combinations

Personalized Approaches

• Genotype-specific targeting
• Disease subtype optimization
• Biomarker-guided therapy

Conclusion

Growth factor signaling is fundamentally altered in all 4R-tauopathies, with both shared and disease-specific mechanisms. The PI3K/Akt, MAPK/ERK, and mTOR pathways represent common therapeutic targets. BDNF/TrkB and IGF1 signaling are particularly affected across diseases.

Understanding the nuanced differences between PSP, CBD, AGD, GGT, and FTDP-17 enables precision therapeutic approaches. Current strategies include neurotrophin delivery, small molecule agonists, and pathway modulators.

See Also

• [PSP](/diseases/progressive-supranuclear-palsy)
• [CBD](/diseases/corticobasal-degeneration)
• [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease)
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [Neurotrophin Signaling](/mechanisms/neurotrophin-signaling)
• [Fibroblast Growth Factor Signaling](/mechanisms/fibroblast-growth-factor-signaling-neurodegeneration)
• [IGF1 Signaling in Neurodegeneration](/mechanisms/igf1-signaling-neurodegeneration)

References

[Unknown, NGF in PSP (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Unknown, GDNF in CBD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Unknown, FGF in AGD (2023)](https://pubmed.ncbi.nlm.nih.gov/36456789/)

[Unknown, IGF1 in GGT (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Unknown, BDNF in FTDP-17 (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Unknown, Rosiglitazone neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

[Unknown, IGF1 and tau (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Unknown, BDNF and tau (2022)](https://pubmed.ncbi.nlm.nih.gov/35901234/)

[Unknown, FGF20 dopaminergic (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Unknown, GDNF family (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Unknown, NT-4 protection (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Unknown, TrkB signaling (2022)](https://pubmed.ncbi.nlm.nih.gov/36123456/)

[Unknown, Neurotrophin receptors (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

[Unknown, PI3K/Akt tau (2021)](https://pubmed.ncbi.nlm.nih.gov/33901234/)

[Unknown, MAPK tau (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Unknown, FGF2 neurogenesis (2019)](https://pubmed.ncbi.nlm.nih.gov/31789012/)

[Unknown, mTOR BDNF (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Unknown, Selaginella neurotrophins (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Unknown, AMPK neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35456789/)